Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia

• Status: Enrolling by invitation
• Trial end date: 2022-02-20
• Target enrollment: 0
• Participant gender: Female

Summary

This study evaluates the addition of Acipimox or placebo to exercise on growth hormone release and ghrelin secretion in bulimic patients and in healthy women. Two groups of participants will receive Acipimox together with exercise versus identical placebo with exercise.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Charles University, Czech Republic
• Treatments: Acipimox

Criteria

Inclusion Criteria:

• Patients with a diagnosis of bulimia nervosa

• Body mass index (BMI) between 18 and 23 kg/m2

Exclusion Criteria:

• History of heart disease

• History of bleeding disorders

• Subjects with diabetes type 1 or 2, hypo- or hyperthyroidism

• Subjects with hepatogastroenteric disease

• Pregnant, trying to become pregnant or breast feeding

• Patients with other psychiatric diseases